* Veracyte Inc VCYT.OQ VCYT.O is expected to show a rise
in
quarterly revenue when it reports results on February 28.
* The South San Francisco California-based company is
expected to
report a 78.9% increase in revenue to $61.785 million from
$34.54 million a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Veracyte Inc is for
a
loss of 16 cents per share. For the same quarter last year, the
company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Veracyte
Inc is
$53.5, about 51.1% above its last closing price of $26.16.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.17 -0.16 -0.20 Missed -21.2
Jun. 30 2021 -0.25 -0.25 -0.13 Beat 48.4
Mar. 31 2021 -0.12 -0.12 -0.11 Beat 8.3
Dec. 31 2020 -0.10 -0.11 -0.14 Missed -30.2
Sep. -0.20 -0.21 -0.08 Beat 61.9
30 2020
Jun. 30 2020 -0.27 -0.24 -0.22 Beat 9.8
Mar. 31 2020 -0.19 -0.20 -0.24 Missed -22
Dec. 31 2019 -0.07 -0.07 -0.15 Missed -100
This summary was machine generated February 25 at 22:40 GMT.
All figures in US dollars unless otherwise stated